CL2017002913A1 - Tratamiento de la hipoglucemia posbariátrica con exendina (9-39) - Google Patents

Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)

Info

Publication number
CL2017002913A1
CL2017002913A1 CL2017002913A CL2017002913A CL2017002913A1 CL 2017002913 A1 CL2017002913 A1 CL 2017002913A1 CL 2017002913 A CL2017002913 A CL 2017002913A CL 2017002913 A CL2017002913 A CL 2017002913A CL 2017002913 A1 CL2017002913 A1 CL 2017002913A1
Authority
CL
Chile
Prior art keywords
postbariatric
exendin
hypoglycemia
treatment
hypoglucemia
Prior art date
Application number
CL2017002913A
Other languages
English (en)
Inventor
Tracey L Mclaughlin
Colleen M Craig
Original Assignee
The Bot Of The Leland Stanford Junior Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Bot Of The Leland Stanford Junior Univ filed Critical The Bot Of The Leland Stanford Junior Univ
Publication of CL2017002913A1 publication Critical patent/CL2017002913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

<p>SE PROPORCIONAN COMPOSICIONES Y MÉTODOS PARA TRATAR LA HIPOGLUCEMIA HIPERINSULINÉMICA, TAL COMO LA HIPOGLUCEMIA HIPERINSULINÉMICA DESPUÉS DE LA CIRUGÍA BARIÁTRICA. EN ALGUNAS MODALIDADES, UNA CANTIDAD EFICAZ DEL ANTAGONISTA DEL RECEPTOR DEL PÉPTIDO SIMILAR AL GLUCAGÓN TIPO 1, EXENDINA (9-39), SE ADMINISTRA POR VÍA SUBCUTÁNEA DOS VECES AL DÍA.</p>
CL2017002913A 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con exendina (9-39) CL2017002913A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29

Publications (1)

Publication Number Publication Date
CL2017002913A1 true CL2017002913A1 (es) 2018-06-01

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002913A CL2017002913A1 (es) 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)
CL2017002911A CL2017002911A1 (es) 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002911A CL2017002911A1 (es) 2015-05-22 2017-11-16 Tratamiento de la hipoglucemia posbariátrica con antagonistas de glp-1.

Country Status (19)

Country Link
US (10) US10660937B2 (es)
EP (5) EP3978011B1 (es)
AU (6) AU2016267052B2 (es)
BR (2) BR112017024997A2 (es)
CA (2) CA3024353A1 (es)
CL (2) CL2017002913A1 (es)
CY (2) CY1124616T1 (es)
DK (3) DK3297653T3 (es)
ES (2) ES2897955T3 (es)
FI (1) FI3978011T3 (es)
HR (2) HRP20211285T1 (es)
HU (2) HUE055728T2 (es)
LT (3) LT3297653T (es)
PL (2) PL3297654T3 (es)
PT (2) PT3297654T (es)
RS (3) RS68222B1 (es)
SI (3) SI3978011T1 (es)
SM (2) SMT202100488T1 (es)
WO (2) WO2016191394A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
CN111936159A (zh) * 2018-01-23 2020-11-13 Xeris药物公司 使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
CN112867730A (zh) * 2018-10-15 2021-05-28 艾格尔峰生物制药有限公司 用于治疗高胰岛素低血糖症的阿维西特
WO2020144378A1 (en) * 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof
WO2024220962A1 (en) * 2023-04-21 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Glp-1r antagonism to improve nutrition following gastrointestinal surgery
WO2025235995A1 (en) * 2024-05-10 2025-11-13 The Board Of Trustees Of The Leland Stanford Junior University Use of glp-1 receptor agonists alone or in combination with other gastrointestinal hormones that delay gastric emptying for treatment of postbariatric hypoglycemia
US20260151460A1 (en) * 2024-12-02 2026-06-04 Amylyx Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306551A (pt) 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ,インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
JP3270761B2 (ja) 1998-01-30 2002-04-02 ノボ ノルディスク アクティーゼルスカブ 注射器
PT1137413E (pt) 1998-12-10 2005-05-31 Agouron Pharma Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
JP2002538084A (ja) 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ,インコーポレイテッド グルカゴンを抑制する方法
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
JP4398644B2 (ja) 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ErbB界面ペプチド擬態およびその使用方法
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
EP1609479A4 (en) 2003-03-13 2010-01-20 Mitsubishi Tanabe Pharma Corp Tumorigenesis INHIBITOR
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN1968700A (zh) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
MX2008015107A (es) 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
EP3456340B1 (en) * 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
US9314508B2 (en) * 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
CN102378632A (zh) 2009-04-03 2012-03-14 雀巢产品技术援助有限公司 对促进健康的追赶生长的改进
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2768856A4 (en) 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE
EP2817025A2 (en) 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Treatment of hypoglycemia
JP6265970B2 (ja) 2012-03-26 2018-01-24 サノフイ 安定なIgG4に基づく結合剤の製剤
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
CN119654159A (zh) 2022-08-05 2025-03-18 印第安纳大学研究与技术公司 胰高血糖素样肽-1受体拮抗剂

Also Published As

Publication number Publication date
US20250255935A1 (en) 2025-08-14
AU2016267057B2 (en) 2021-12-23
US20250082730A1 (en) 2025-03-13
AU2016267052A1 (en) 2017-12-14
US11617782B2 (en) 2023-04-04
US10639354B2 (en) 2020-05-05
AU2016267057A1 (en) 2017-12-14
EP3297654A4 (en) 2018-04-11
SI3297654T1 (sl) 2021-11-30
PT3297654T (pt) 2021-09-06
US20200276271A1 (en) 2020-09-03
FI3978011T3 (fi) 2026-06-12
AU2022202506A1 (en) 2022-05-12
CA3024353A1 (en) 2016-12-01
SMT202100668T1 (it) 2022-01-10
HUE055728T2 (hu) 2021-12-28
CY1125147T1 (el) 2023-03-24
SI3297653T1 (sl) 2022-01-31
US10993991B2 (en) 2021-05-04
RS62627B1 (sr) 2021-12-31
HRP20211285T1 (hr) 2022-01-07
CA3024358A1 (en) 2016-12-01
RS62368B1 (sr) 2021-10-29
EP3297653A4 (en) 2018-12-26
CY1124616T1 (el) 2022-07-22
AU2022202506B2 (en) 2025-06-05
SI3978011T1 (sl) 2026-07-31
BR112017024997A2 (pt) 2018-07-31
AU2016267052B2 (en) 2022-01-20
US11622995B2 (en) 2023-04-11
EP3978011B1 (en) 2026-05-06
EP3936143A1 (en) 2022-01-12
WO2016191394A1 (en) 2016-12-01
BR112017025000A2 (pt) 2018-08-07
US20210290731A1 (en) 2021-09-23
EP4782057A2 (en) 2026-07-29
SMT202100488T1 (it) 2021-11-12
HRP20211768T1 (hr) 2022-02-18
HUE057301T2 (hu) 2022-05-28
DK3978011T3 (da) 2026-07-20
EP3297653A1 (en) 2018-03-28
AU2025217292A1 (en) 2025-09-04
LT3297653T (lt) 2022-01-10
WO2016191395A1 (en) 2016-12-01
AU2022201973B2 (en) 2025-05-15
LT3297654T (lt) 2021-10-25
DK3297653T3 (da) 2021-10-18
PT3297653T (pt) 2021-10-25
US20200276272A1 (en) 2020-09-03
PL3297654T3 (pl) 2021-12-20
ES2897955T3 (es) 2022-03-03
US20210315974A1 (en) 2021-10-14
EP3297653B1 (en) 2021-09-15
US20180147261A1 (en) 2018-05-31
ES2887723T3 (es) 2021-12-27
RS68222B1 (en) 2026-07-31
LT3978011T (lt) 2026-08-10
US20180117122A1 (en) 2018-05-03
EP3297654A1 (en) 2018-03-28
US20240000894A1 (en) 2024-01-04
PL3297653T3 (pl) 2022-01-31
US10660937B2 (en) 2020-05-26
DK3297654T3 (da) 2021-09-06
US10993992B2 (en) 2021-05-04
US12102663B2 (en) 2024-10-01
AU2025220813A1 (en) 2025-09-11
CL2017002911A1 (es) 2018-05-25
EP3978011A1 (en) 2022-04-06
US20230346890A1 (en) 2023-11-02
AU2022201973A1 (en) 2022-04-14
EP3297654B1 (en) 2021-07-07
US12220444B2 (en) 2025-02-11

Similar Documents

Publication Publication Date Title
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MY187047A (en) Selective pyy compounds and uses thereof
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
MX375431B (es) Virus de la enfermedad de newcastle y usos de los mismos.
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1124616T1 (el) Θεραπεια της μετα-βαριατρικης υπογλυκαιμιας με εξενδινη(9-39)
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2017001718A1 (es) Derivados de glucagón con estabilidad mejorada
AR102712A1 (es) Agonistas parciales del receptor de insulina
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201890149A1 (ru) Композиции криопреципитатов и способы их получения
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CL2015002897A1 (es) Inhibidores de bace1
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX2018001720A (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.